Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment

Yasuteru Kondo(Sendai Kousei Hospital), Yasuhito Tanaka(Kumamoto University), Hiroaki Satio(Sendai Kousei Hospital), Jun‐ichi Akahira, Tatsuki Morosawa(Sendai Kousei Hospital), Akashi Endo(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yukihiro Toi(Sendai Kousei Hospital), Mareyuki Endo(Tohoku University)
Scientific Reports
March 7, 2022
10.1038/s41598-022-07770-8
Cited by 8

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642